Table 4.
Some key mode and resource use with antimicrobials specific for resistant Gram-positive infections. Linezolid compared with standard of care antimicrobials for methicillin-resistant Gram-positive cocci infections (vancomycin and teicoplanin), and with the currently available alternatives recently introduced into the market (quinupristin/dalfopristin, and daptomycin)
Linezolid | Vancomycin | Teicoplanin | Quinupristin/dalfopristin | Daptomycin | Tigecycline | Dalbavancin | |
---|---|---|---|---|---|---|---|
IV and oral route, both available | Yes | No* | No* | No | No | No | No |
Ambulatory (outpatient) | Yes | No | Yes | Yes? | ? | ? | Yes |
administration feasible | |||||||
Need of serum drug level monitoring | No | Yes | No | Yes | Yes? | No | No |
Frequency of drug administration | Twice daily | At least twice daily, to 24 h continue infusion | Once daily | Once daily | Once daily | Twice daily | Once weekly |
Abbreviations: IV, intravenous.
Note: indication restricted to the management of Clostridium difficile-associated diarrhea.